Stay updated with breaking news from Targeted Protein. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The field of protein degraders is at an inflection point as more degraders enter the clinical space. Evaluating the patent filing activity will play a critical role in the ability to managing opportunities for licensing and partnerships.
Targeted protein degraders such as proteolysis targeting chimeras (PROTACs) have been a significant development in the therapeutics space. These…
/PRNewswire/ -- The "Emerging Landscape of Targeted Protein Degradation Therapeutics" report has been added to ResearchAndMarkets.com's offering. Advancing...
/PRNewswire/ -- Biotheryx, Inc., a clinical stage company discovering and developing a portfolio of innovative small molecule targeted protein degraders (TPDs)...
Amphista Therapeutics creates treatments that help harness the body’s natural processes to degrade proteins that cause diseases.